Literature DB >> 17327408

Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival.

James R Cerhan1, Sophia Wang, Matthew J Maurer, Stephen M Ansell, Susan M Geyer, Wendy Cozen, Lindsay M Morton, Scott Davis, Richard K Severson, Nathaniel Rothman, Charles F Lynch, Sholom Wacholder, Stephen J Chanock, Thomas M Habermann, Patricia Hartge.   

Abstract

Recent gene-expression data have suggested that host immune genetic signatures may predict outcomes in patients with follicular lymphoma. We evaluated the hypothesis that germ line common variation in candidate immune genes is associated with survival. Cox models were used to estimate hazard ratios (HR) and corresponding 95% confidence intervals for individual SNPs after accounting for age, clinical, and other demographic factors. The median age at diagnosis of the 278 patients was 57 years, and 59 (21%) of the patients died during follow-up, with a median follow-up of 59 months (range, 27-78 months) for surviving patients. SNPs in IL8 (rs4073; HR(TT)=2.14, 1.26-3.63), IL2 (rs2069762; HR(GT/TT) = 1.80, 1.06-3.05), IL12B (rs3212227; HR(AC/CC)=1.83, 1.06-3.06), and IL1RN (rs454078; HR(AA)=1.93, 1.11-3.34) were the most robust predictors of survival. A summary score of the number of deleterious genotypes from these genes was strongly associated with survival (P=.001). A risk score that combined the 4 SNPs with the clinical and demographic factors was even more strongly associated with survival (P<.001); the 5-year Kaplan-Meier survival estimates were 96% (93%-100%), 72% (62%-83%), and 58% (48%-72%) for groups at low, intermediate, and high risk, respectively. Common variation in host immune genes warrants further evaluation as a promising class of prognostic factors in follicular lymphoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17327408      PMCID: PMC1890834          DOI: 10.1182/blood-2006-11-058040

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  48 in total

1.  Prognosis in follicular lymphoma--it's in the microenvironment.

Authors:  Ralf Küppers
Journal:  N Engl J Med       Date:  2004-11-18       Impact factor: 91.245

2.  A bootstrap resampling procedure for model building: application to the Cox regression model.

Authors:  W Sauerbrei; M Schumacher
Journal:  Stat Med       Date:  1992-12       Impact factor: 2.373

3.  Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome.

Authors:  K Warzocha; P Ribeiro; J Bienvenu; P Roy; C Charlot; D Rigal; B Coiffier; G Salles
Journal:  Blood       Date:  1998-05-15       Impact factor: 22.113

4.  Clinico-biological implications of increased serum levels of interleukin-8 in B-cell chronic lymphocytic leukemia.

Authors:  S Molica; G Vitelli; D Levato; L Levato; A Dattilo; G M Gandolfo
Journal:  Haematologica       Date:  1999-03       Impact factor: 9.941

5.  Expression of interleukin-8 correlates with vascularity in human gastric carcinomas.

Authors:  Y Kitadai; K Haruma; K Sumii; S Yamamoto; T Ue; H Yokozaki; W Yasui; Y Ohmoto; G Kajiyama; I J Fidler; E Tahara
Journal:  Am J Pathol       Date:  1998-01       Impact factor: 4.307

Review 6.  Follicular lymphoma: time for a re-think?

Authors:  Maher K Gandhi; Robert E Marcus
Journal:  Blood Rev       Date:  2005-05       Impact factor: 8.250

7.  Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment.

Authors:  Annuska M Glas; Marie José Kersten; Leonie J M J Delahaye; Anke T Witteveen; Robby E Kibbelaar; Arno Velds; Lodewyk F A Wessels; Peter Joosten; Ron M Kerkhoven; René Bernards; Johan H J M van Krieken; Philip M Kluin; Laura J van't Veer; Daphne de Jong
Journal:  Blood       Date:  2004-09-02       Impact factor: 22.113

Review 8.  Cytokines in the pathophysiology and treatment of chronic B-cell malignancies. A review.

Authors:  M Schuler; C Huber; C Peschel
Journal:  Ann Hematol       Date:  1995-08       Impact factor: 3.673

Review 9.  Cytokine deregulation in hematological malignancies: clinical and biological implications.

Authors:  R Kurzrock
Journal:  Clin Cancer Res       Date:  1997-12       Impact factor: 12.531

10.  Serum levels of cytokines in patients with colorectal cancer: possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis.

Authors:  T Ueda; E Shimada; T Urakawa
Journal:  J Gastroenterol       Date:  1994-08       Impact factor: 7.527

View more
  41 in total

Review 1.  Do recent reports of prolonged survival in patients with follicular lymphoma suggest that deferral of therapy is no longer justifiable?

Authors:  Brian K Link
Journal:  Curr Hematol Malig Rep       Date:  2007-10       Impact factor: 3.952

2.  Bayesian ensemble methods for survival prediction in gene expression data.

Authors:  Vinicius Bonato; Veerabhadran Baladandayuthapani; Bradley M Broom; Erik P Sulman; Kenneth D Aldape; Kim-Anh Do
Journal:  Bioinformatics       Date:  2010-12-08       Impact factor: 6.937

Review 3.  The secret ally: immunostimulation by anticancer drugs.

Authors:  Lorenzo Galluzzi; Laura Senovilla; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Rev Drug Discov       Date:  2012-02-03       Impact factor: 84.694

4.  Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era.

Authors:  Thomas M Habermann; Sophia S Wang; Matthew J Maurer; Lindsay M Morton; Charles F Lynch; Stephen M Ansell; Patricia Hartge; Richard K Severson; Nathaniel Rothman; Scott Davis; Susan M Geyer; Wendy Cozen; Stephen J Chanock; James R Cerhan
Journal:  Blood       Date:  2008-07-16       Impact factor: 22.113

5.  Contribution of IL12A and IL12B polymorphisms to the risk of cervical cancer.

Authors:  Andrzej Roszak; Adrianna Mostowska; Anna Sowińska; Margarita Lianeri; Pawel P Jagodziński
Journal:  Pathol Oncol Res       Date:  2012-05-22       Impact factor: 3.201

6.  Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: results from two independent cohorts.

Authors:  Hervé Ghesquières; Matthew J Maurer; Olivier Casasnovas; Stephen M Ansell; Beth R Larrabee; Eva Lech-Maranda; Anne J Novak; Anne-Laure Borrel; Susan L Slager; Pauline Brice; Cristine Allmer; Annie Brion; Steven C Ziesmer; Franck Morschhauser; Thomas M Habermann; Isabelle Gaillard; Brian K Link; Aspasia Stamatoullas; Christophe Fermé; Ahmet Dogan; William R Macon; Josée Audouin; James R Cerhan; Gilles Salles
Journal:  Cytokine       Date:  2013-09-03       Impact factor: 3.861

Review 7.  Host genetics in follicular lymphoma.

Authors:  James R Cerhan
Journal:  Best Pract Res Clin Haematol       Date:  2011-05-05       Impact factor: 3.020

8.  Rural and urban patients with diffuse large B-cell and follicular lymphoma experience reduced overall survival: a National Cancer DataBase study.

Authors:  Andrew J Ritter; Jordan S Goldstein; Amy A Ayers; Christopher R Flowers
Journal:  Leuk Lymphoma       Date:  2019-01-11

9.  Inherited genetic variation and overall survival following follicular lymphoma.

Authors:  Todd M Gibson; Sophia S Wang; James R Cerhan; Matthew J Maurer; Patricia Hartge; Thomas M Habermann; Scott Davis; Wendy Cozen; Charles F Lynch; Richard K Severson; Nathaniel Rothman; Stephen J Chanock; Lindsay M Morton
Journal:  Am J Hematol       Date:  2012-03-31       Impact factor: 10.047

10.  Follicular lymphoma B cells induce the conversion of conventional CD4+ T cells to T-regulatory cells.

Authors:  Weiyun Z Ai; Jing-Zhou Hou; Robert Zeiser; Debra Czerwinski; Robert S Negrin; Ronald Levy
Journal:  Int J Cancer       Date:  2009-01-01       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.